Cargando…
Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B()
OBJECTIVE: Amphotericin B (AMB), a potent antifungal agent, has been employed as topical and systemic therapy for sinonasal fungal infections. A novel formulation of nanodisc (ND) containing super aggregated AMB (ND-AMB) for the treatment of fungal infections has been recently developed to provide g...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683641/ https://www.ncbi.nlm.nih.gov/pubmed/29204573 http://dx.doi.org/10.1016/j.wjorl.2017.01.002 |
_version_ | 1783278330994229248 |
---|---|
author | Cho, Do-Yeon Hoffman, Kyle J. Gill, Gobind S. Lim, Dong-Jin Skinner, Daniel Mackey, Calvin Rowe, Steven M. Woodworth, Bradford A. |
author_facet | Cho, Do-Yeon Hoffman, Kyle J. Gill, Gobind S. Lim, Dong-Jin Skinner, Daniel Mackey, Calvin Rowe, Steven M. Woodworth, Bradford A. |
author_sort | Cho, Do-Yeon |
collection | PubMed |
description | OBJECTIVE: Amphotericin B (AMB), a potent antifungal agent, has been employed as topical and systemic therapy for sinonasal fungal infections. A novel formulation of nanodisc (ND) containing super aggregated AMB (ND-AMB) for the treatment of fungal infections has been recently developed to provide greater protection from AMB toxicity than current, clinically approved lipid-based formulations. The objective of the current study was to evaluate the safety and potency of ND-AMB for sinonasal delivery using an in vitro model. METHODS: Human sinonasal tissue was harvested during endoscopic sinus surgery and grown at air–liquid interface until well-differentiated. Cultures were exposed to ND-AMB vs AMB and changes in K(+) permeability and resistance were measured and recorded via Ussing chamber assay. Ciliary beat frequency (CBF) was analyzed in parallel as well as cytotoxic assay. Potency was assessed using real-time PCR measurement of the Aspergillus fumigatus 18S rRNA. RESULTS: Ussing chamber studies revealed K(+) currents that increased rapidly within 30 s of adding AMB (10 μg/mL) to the apical side, indicating apical membranes had become permeable to K(+) ions. In contrast, negligible induction of K(+) current was obtained following addition of ND-AMB [AMB = (107.7 ± 15.9) μA/cm(2) AMB vs ND-AMB = (2.3 ± 0.7) μA/cm(2) ND-AMB; P = 0.005]. ND-AMB also protected nasal epithelial cells from cytotoxicity of AMB (P < 0.05). There was no difference in ciliary beat frequency between the two groups (P = 0.96). The expression of A. fumigatus 18S rRNA with exposure of lower dose of ND-AMB was significantly lower compared to that with AMB (P < 0.05). CONCLUSIONS: Data from the present study suggests ND-AMB protects human nasal epithelia membranes from AMB toxicity by protecting against apical cell K(+) permeability while maintaining uncompromised antifungal property compared to AMB. ND-AMB could provide a novel topical therapy for sinonasal fungal diseases. |
format | Online Article Text |
id | pubmed-5683641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-56836412017-12-04 Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B() Cho, Do-Yeon Hoffman, Kyle J. Gill, Gobind S. Lim, Dong-Jin Skinner, Daniel Mackey, Calvin Rowe, Steven M. Woodworth, Bradford A. World J Otorhinolaryngol Head Neck Surg Research Paper OBJECTIVE: Amphotericin B (AMB), a potent antifungal agent, has been employed as topical and systemic therapy for sinonasal fungal infections. A novel formulation of nanodisc (ND) containing super aggregated AMB (ND-AMB) for the treatment of fungal infections has been recently developed to provide greater protection from AMB toxicity than current, clinically approved lipid-based formulations. The objective of the current study was to evaluate the safety and potency of ND-AMB for sinonasal delivery using an in vitro model. METHODS: Human sinonasal tissue was harvested during endoscopic sinus surgery and grown at air–liquid interface until well-differentiated. Cultures were exposed to ND-AMB vs AMB and changes in K(+) permeability and resistance were measured and recorded via Ussing chamber assay. Ciliary beat frequency (CBF) was analyzed in parallel as well as cytotoxic assay. Potency was assessed using real-time PCR measurement of the Aspergillus fumigatus 18S rRNA. RESULTS: Ussing chamber studies revealed K(+) currents that increased rapidly within 30 s of adding AMB (10 μg/mL) to the apical side, indicating apical membranes had become permeable to K(+) ions. In contrast, negligible induction of K(+) current was obtained following addition of ND-AMB [AMB = (107.7 ± 15.9) μA/cm(2) AMB vs ND-AMB = (2.3 ± 0.7) μA/cm(2) ND-AMB; P = 0.005]. ND-AMB also protected nasal epithelial cells from cytotoxicity of AMB (P < 0.05). There was no difference in ciliary beat frequency between the two groups (P = 0.96). The expression of A. fumigatus 18S rRNA with exposure of lower dose of ND-AMB was significantly lower compared to that with AMB (P < 0.05). CONCLUSIONS: Data from the present study suggests ND-AMB protects human nasal epithelia membranes from AMB toxicity by protecting against apical cell K(+) permeability while maintaining uncompromised antifungal property compared to AMB. ND-AMB could provide a novel topical therapy for sinonasal fungal diseases. KeAi Publishing 2017-03-07 /pmc/articles/PMC5683641/ /pubmed/29204573 http://dx.doi.org/10.1016/j.wjorl.2017.01.002 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Cho, Do-Yeon Hoffman, Kyle J. Gill, Gobind S. Lim, Dong-Jin Skinner, Daniel Mackey, Calvin Rowe, Steven M. Woodworth, Bradford A. Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B() |
title | Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B() |
title_full | Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B() |
title_fullStr | Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B() |
title_full_unstemmed | Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B() |
title_short | Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B() |
title_sort | protective and antifungal properties of nanodisk-amphotericin b over commercially available amphotericin b() |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683641/ https://www.ncbi.nlm.nih.gov/pubmed/29204573 http://dx.doi.org/10.1016/j.wjorl.2017.01.002 |
work_keys_str_mv | AT chodoyeon protectiveandantifungalpropertiesofnanodiskamphotericinbovercommerciallyavailableamphotericinb AT hoffmankylej protectiveandantifungalpropertiesofnanodiskamphotericinbovercommerciallyavailableamphotericinb AT gillgobinds protectiveandantifungalpropertiesofnanodiskamphotericinbovercommerciallyavailableamphotericinb AT limdongjin protectiveandantifungalpropertiesofnanodiskamphotericinbovercommerciallyavailableamphotericinb AT skinnerdaniel protectiveandantifungalpropertiesofnanodiskamphotericinbovercommerciallyavailableamphotericinb AT mackeycalvin protectiveandantifungalpropertiesofnanodiskamphotericinbovercommerciallyavailableamphotericinb AT rowestevenm protectiveandantifungalpropertiesofnanodiskamphotericinbovercommerciallyavailableamphotericinb AT woodworthbradforda protectiveandantifungalpropertiesofnanodiskamphotericinbovercommerciallyavailableamphotericinb |